Alvotech Reaffirms 2025 Outlook, Issues 2026 Guidance
Ticker: ALVOW · Form: 6-K · Filed: Dec 17, 2025 · CIK: 1898416
| Field | Detail |
|---|---|
| Company | Alvotech (ALVOW) |
| Form Type | 6-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $570, $600 million, $130, $150 million, $650 |
| Sentiment | neutral |
Sentiment: neutral
Topics: business-update, guidance, financial-performance
TL;DR
Alvotech sticks to 2025 revenue forecast and gives a peek at 2026 numbers.
AI Summary
On December 16, 2025, Alvotech provided a business update, reaffirming its full-year 2025 revenue outlook previously updated on November 2, 2025. The company also issued financial guidance for the fourth quarter of 2025 and the full fiscal year 2026.
Why It Matters
This update provides investors with clarity on Alvotech's near-term financial performance and future expectations, crucial for valuation and investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine business update and financial guidance, not indicating any immediate material adverse events.
Key Players & Entities
- Alvotech (company) — Registrant
- December 16, 2025 (date) — Date of business update
- November 2, 2025 (date) — Date of previous revenue outlook update
FAQ
What was the specific revenue outlook reaffirmed for the full year 2025?
The filing states that the full year outlook for 2025 was reaffirmed as updated on November 2, 2025, but does not provide the specific dollar amount in this excerpt.
When did Alvotech provide its previous revenue outlook update?
Alvotech previously updated its revenue outlook on November 2, 2025.
What period does the new financial guidance cover?
The new financial guidance covers the fourth quarter of 2025 and the full fiscal year 2026.
What is Alvotech's primary business?
Alvotech is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Where is Alvotech's principal executive office located?
Alvotech's principal executive office is located at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg.
Filing Stats: 1,402 words · 6 min read · ~5 pages · Grade level 13.9 · Accepted 2025-12-17 08:37:44
Key Financial Figures
- $570 — revenues in 2025 to be in the range of $570 to $600 million and adjusted EBITDA in
- $600 million — s in 2025 to be in the range of $570 to $600 million and adjusted EBITDA in the range of $13
- $130 — ion and adjusted EBITDA in the range of $130 to $150 million. For 2026, the Company
- $150 million — adjusted EBITDA in the range of $130 to $150 million. For 2026, the Company anticipates tota
- $650 — icipates total revenues in the range of $650-$700 million and expects adjusted EBITD
- $700 million — tes total revenues in the range of $650-$700 million and expects adjusted EBITDA to increase
- $180 — expects adjusted EBITDA to increase to $180-$220 million. The guidance for 2026 tak
- $220 million — cts adjusted EBITDA to increase to $180-$220 million. The guidance for 2026 takes into accou
- $108 million — shore offering (the "Bond Offering") of $108 million senior unsecured convertible bonds due
- $200,000 — rear, issued at par in denominations of $200,000, and are convertible from the 41st day
- $5.9224 — s") with an initial conversion price of $5.9224 per SDR (a premium of 25% over the refe
- $4.7379 — mium of 25% over the reference price of $4.7379 per SDR). The Company may call the Conv
Filing Documents
- f6k_121725.htm (6-K) — 16KB
- exh_991.htm (EX-99.1) — 26KB
- 0001171843-25-007974.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alvotech (Registrant) Date: December 17, 2025 /s/ Tanya Zharov Tanya Zharov General Counsel